Section 6 of 6
References
220 sources
- Abdeen et al. (2026) (opens in a new tab)
- Aetna Wegovy precertification policy (2026) (opens in a new tab)
- Aggio et al. (2024) (opens in a new tab)
- Akbari et al. (2024) (opens in a new tab)
- Alaska Medicaid Rezdiffra criteria (2026) (opens in a new tab)
- Alp et al. (2025) (opens in a new tab)
- Altimmune PERFORMA initiation release (2026) (opens in a new tab)
- American Diabetes Association Professional Practice Committee (2026) (opens in a new tab)
- Aminian et al. (2021) (opens in a new tab)
- Angulo et al. (2015) (opens in a new tab)
- Augusto et al. (2026) (opens in a new tab)
- Bansal et al. (2026) (opens in a new tab)
- Barb et al. (2023) (opens in a new tab)
- Barb et al. (2025) (opens in a new tab)
- Boubia et al. (2018) (opens in a new tab)
- Boursier et al. (2025) (opens in a new tab)
- Boyer-Diaz et al. (2021) (opens in a new tab)
- Caussy et al. (2025) (opens in a new tab)
- CDC FastStats chronic liver disease and cirrhosis (2026) (opens in a new tab)
- Chen et al. (2025) (opens in a new tab)
- Chen et al. (2026) (opens in a new tab)
- Cigna Rezdiffra prior authorization policy (2026) (opens in a new tab)
- ClinicalTrials.gov NCT03008070 (opens in a new tab)
- ClinicalTrials.gov NCT03008070 API record (opens in a new tab)
- ClinicalTrials.gov NCT03008070 results (opens in a new tab)
- ClinicalTrials.gov NCT03459079 (opens in a new tab)
- ClinicalTrials.gov NCT03459079 results (opens in a new tab)
- ClinicalTrials.gov NCT03866369 (opens in a new tab)
- ClinicalTrials.gov NCT04849728 (opens in a new tab)
- ClinicalTrials.gov NCT04849728 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT04849728 version 15 (opens in a new tab)
- ClinicalTrials.gov NCT04849728 version 16 (opens in a new tab)
- ClinicalTrials.gov NCT05232071 (opens in a new tab)
- ClinicalTrials.gov NCT05232071 API record (opens in a new tab)
- ClinicalTrials.gov NCT05232071 results (opens in a new tab)
- ClinicalTrials.gov NCT06126562 (opens in a new tab)
- ClinicalTrials.gov NCT06215716 (opens in a new tab)
- ClinicalTrials.gov NCT06318169 (opens in a new tab)
- ClinicalTrials.gov NCT06594523 (opens in a new tab)
- ClinicalTrials.gov NCT06632444 (opens in a new tab)
- ClinicalTrials.gov NCT07165028 (opens in a new tab)
- ClinicalTrials.gov NCT07221227 (opens in a new tab)
- ClinicalTrials.gov NCT07795164 (opens in a new tab)
- Cooreman et al. (2024) (opens in a new tab)
- Cusi et al. (2016) (opens in a new tab)
- Cusi et al. (2022) (opens in a new tab)
- David et al. (2009) (opens in a new tab)
- Davison et al. (2020) (opens in a new tab)
- Duell et al. (2022) (opens in a new tab)
- Dulai et al. (2017) (opens in a new tab)
- Estes et al. (2018) (opens in a new tab)
- EU Clinical Trials Information System 2023-508248-23-00 (opens in a new tab)
- EU Clinical Trials Information System 2025-524385-18-00 (opens in a new tab)
- European Association for the Study of the Liver (2024) (opens in a new tab)
- European Medicines Agency NASH reflection paper (2024) (opens in a new tab)
- FDA (2018) (opens in a new tab)
- FDA (2025) (opens in a new tab)
- Fishman et al. (2024a) (opens in a new tab)
- Fishman et al. (2024b) (opens in a new tab)
- Francque et al. (2020) (opens in a new tab)
- Francque et al. (2021) (opens in a new tab)
- Francque et al. (2026) (opens in a new tab)
- Friedman et al. (2018) (opens in a new tab)
- Gordon et al. (2020) (opens in a new tab)
- Griffel et al. (2023) (opens in a new tab)
- GSK efimosfermin Breakthrough Therapy and PRIME designation release (2026) (opens in a new tab)
- Guo et al. (2026) (opens in a new tab)
- Harrison et al. (2023) (opens in a new tab)
- Harrison et al. (2024) (opens in a new tab)
- Holleboom et al. (2026) (opens in a new tab)
- Huang et al. (2025) (opens in a new tab)
- ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023) (opens in a new tab)
- ICER Final Policy Recommendations, NASH (2023) (opens in a new tab)
- Inventiva AASLD 2025 abstracts release (2025) (opens in a new tab)
- Inventiva AASLD 2026 abstracts release (2026) (opens in a new tab)
- Inventiva Breakthrough Therapy designation release (2020) (opens in a new tab)
- Inventiva clinical development changes release (2023) (opens in a new tab)
- Inventiva CTTQ China IND release (2023) (opens in a new tab)
- Inventiva CTTQ milestone release (2025) (opens in a new tab)
- Inventiva debt and equity financing release (2026) (opens in a new tab)
- Inventiva EASL Congress 2026 abstracts release (2026) (opens in a new tab)
- Inventiva EASL SLD 2025 abstract release (2025) (opens in a new tab)
- Inventiva Fast Track compensated cirrhosis release (2021) (opens in a new tab)
- Inventiva Fast Track designation release (2019) (opens in a new tab)
- Inventiva fifth NATiV3 DMC release (2024) (opens in a new tab)
- Inventiva first half 2022 results announcement (2022) (opens in a new tab)
- Inventiva first half 2026 results announcement (2026) (opens in a new tab)
- Inventiva Form 20-F (2026) (opens in a new tab)
- Inventiva fourth NATiV3 DMC release (2024) (opens in a new tab)
- Inventiva full year 2025 results announcement (2026) (opens in a new tab)
- Inventiva Hepalys license release (2023) (opens in a new tab)
- Inventiva Hepalys phase 1 initiation release (2025) (opens in a new tab)
- Inventiva investor and analyst day presentation (2025) (opens in a new tab)
- Inventiva LEGEND AASLD late-breaker release (2024) (opens in a new tab)
- Inventiva LEGEND protocol (2024) (opens in a new tab)
- Inventiva LEGEND statistical analysis plan (2024) (opens in a new tab)
- Inventiva LEGEND topline results release (2024) (opens in a new tab)
- Inventiva NATiV3 and financial update release (2024) (opens in a new tab)
- Inventiva NATiV3 design release (2021) (opens in a new tab)
- Inventiva NATiV3 enrollment completion release (2025) (opens in a new tab)
- Inventiva NATiV3 initiation release (2021) (opens in a new tab)
- Inventiva NATiV3 last patient visit release (2026) (opens in a new tab)
- Inventiva NATiV3 screening resumption release (2024) (opens in a new tab)
- Inventiva NATiV3 status update release (2023) (opens in a new tab)
- Inventiva NATIVE protocol (2019) (opens in a new tab)
- Inventiva NATIVE topline results release (2020) (opens in a new tab)
- Inventiva Paris MASH 2026 abstracts release (2026) (opens in a new tab)
- Inventiva preliminary full year 2023 results announcement (2024) (opens in a new tab)
- Inventiva Sino Biopharm license release (2022) (opens in a new tab)
- Inventiva structured financing release (2024) (opens in a new tab)
- Inventiva third NATiV3 DMC release (2023) (opens in a new tab)
- Inventiva third quarter 2025 results announcement (2025) (opens in a new tab)
- Inventiva University of Florida trial topline release (2023) (opens in a new tab)
- Javanbakht et al. (2023) (opens in a new tab)
- Joszt (2024) (opens in a new tab)
- Kamata et al. (2023) (opens in a new tab)
- Kanwal et al. (2018) (opens in a new tab)
- Kanwal et al. (2021) (opens in a new tab)
- Kim et al. (2025a) (opens in a new tab)
- Kim et al. (2025b) (opens in a new tab)
- Lai et al. (2024) (opens in a new tab)
- Lassailly et al. (2020) (opens in a new tab)
- Lazarus et al. (2025a) (opens in a new tab)
- Lazarus et al. (2025b) (opens in a new tab)
- Le et al. (2022) (opens in a new tab)
- Le et al. (2023) (opens in a new tab)
- Le et al. (2025a) (opens in a new tab)
- Le et al. (2025b) (opens in a new tab)
- Lee et al. (2024) (opens in a new tab)
- Lefere et al. (2020) (opens in a new tab)
- Lin et al. (2025) (opens in a new tab)
- Loomba et al. (2021) (opens in a new tab)
- Loomba et al. (2023) (opens in a new tab)
- Loomba et al. (2024a) (opens in a new tab)
- Loomba et al. (2024b) (opens in a new tab)
- Luthra and Sheth (2025) (opens in a new tab)
- Madrigal Pharmaceuticals Colorado price disclosure (2026) (opens in a new tab)
- Madrigal Pharmaceuticals Connecticut price disclosure, January 2026 (2026) (opens in a new tab)
- Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026) (opens in a new tab)
- Mahady et al. (2012) (opens in a new tab)
- Mangia and Valenti (2025) (opens in a new tab)
- Mantovani et al. (2021) (opens in a new tab)
- Mantovani et al. (2022a) (opens in a new tab)
- Mantovani et al. (2022b) (opens in a new tab)
- Marquardt et al. (2026) (opens in a new tab)
- McGovern et al. (2026) (opens in a new tab)
- Mironova et al. (2026) (opens in a new tab)
- Mittal et al. (2024) (opens in a new tab)
- NCQA (opens in a new tab)
- Newsome et al. (2020) (opens in a new tab)
- Ng et al. (2023) (opens in a new tab)
- Njei et al. (2026) (opens in a new tab)
- Noureddin et al. (2025) (opens in a new tab)
- Noureddin et al. (2026) (opens in a new tab)
- Novo Nordisk (2026) (opens in a new tab)
- Novo Nordisk Akero acquisition completion release (2025) (opens in a new tab)
- Novo Nordisk WEGOVY prescribing information (2026) (opens in a new tab)
- NovoCare MASH list price (2025) (opens in a new tab)
- O'Hara et al. (2020) (opens in a new tab)
- PA Health and Wellness resmetirom clinical policy (2025) (opens in a new tab)
- Papadimopoulos et al. (2026) (opens in a new tab)
- Patel et al. (2025) (opens in a new tab)
- Patel et al. (2026) (opens in a new tab)
- Payne et al. (2023) (opens in a new tab)
- Prime Therapeutics HCSC resmetirom program summary (2026) (opens in a new tab)
- Promrat et al. (2010) (opens in a new tab)
- Pulaski et al. (2024) (opens in a new tab)
- Rautou et al. (2025) (opens in a new tab)
- Ravela et al. (2025) (opens in a new tab)
- Riazi et al. (2022) (opens in a new tab)
- Rinella et al. (2023a) (opens in a new tab)
- Rinella et al. (2023b) (opens in a new tab)
- Rinella et al. (2026a) (opens in a new tab)
- Rinella et al. (2026b) (opens in a new tab)
- Roche 89bio merger agreement release (2025) (opens in a new tab)
- Roche 89bio tender offer release (2025) (opens in a new tab)
- Sabatini and Gastaldelli (2025) (opens in a new tab)
- Sagimet Biosciences strategic and corporate updates release (2026) (opens in a new tab)
- Sanyal et al. (2010) (opens in a new tab)
- Sanyal et al. (2021) (opens in a new tab)
- Sanyal et al. (2024) (opens in a new tab)
- Sanyal et al. (2025) (opens in a new tab)
- Sayiner et al. (2016) (opens in a new tab)
- Sayiner et al. (2017) (opens in a new tab)
- Schneider et al. (2024) (opens in a new tab)
- Shinde et al. (2025) (opens in a new tab)
- Shuaibi et al. (2025) (opens in a new tab)
- Simon et al. (2021) (opens in a new tab)
- Singh et al. (2015) (opens in a new tab)
- Souza et al. (2025) (opens in a new tab)
- Sterling et al. (2025a) (opens in a new tab)
- Sterling et al. (2025b) (opens in a new tab)
- Takeda Pharmaceuticals ACTOS prescribing information (2017) (opens in a new tab)
- Tan et al. (2022) (opens in a new tab)
- Tapper et al. (2023a) (opens in a new tab)
- Tapper et al. (2023b) (opens in a new tab)
- Taylor et al. (2020) (opens in a new tab)
- University of Florida lanifibranor protocol (2022) (opens in a new tab)
- Verrastro et al. (2023) (opens in a new tab)
- Vilar-Gomez et al. (2015) (opens in a new tab)
- Wallace et al. (2025) (opens in a new tab)
- Wettstein et al. (2017) (opens in a new tab)
- WHO Drug Information (2016) (opens in a new tab)
- Wong et al. (2021) (opens in a new tab)
- Younossi et al. (2016a) (opens in a new tab)
- Younossi et al. (2016b) (opens in a new tab)
- Younossi et al. (2017) (opens in a new tab)
- Younossi et al. (2019a) (opens in a new tab)
- Younossi et al. (2019b) (opens in a new tab)
- Younossi et al. (2020) (opens in a new tab)
- Younossi et al. (2021) (opens in a new tab)
- Younossi et al. (2022) (opens in a new tab)
- Younossi et al. (2023) (opens in a new tab)
- Younossi et al. (2025a) (opens in a new tab)
- Younossi et al. (2025b) (opens in a new tab)
- Younossi et al. (2025c) (opens in a new tab)
- Younossi et al. (2025d) (opens in a new tab)
- Younossi et al. (2026a) (opens in a new tab)
- Younossi et al. (2026b) (opens in a new tab)
- Younossi et al. (2026c) (opens in a new tab)